STOCK TITAN

Resmed Inc. - RMD STOCK NEWS

Welcome to our dedicated news page for Resmed (Ticker: RMD), a resource for investors and traders seeking the latest updates and insights on Resmed.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Resmed's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Resmed's position in the market.

Rhea-AI Summary
ResMed Inc. reported strong third-quarter results for fiscal year 2024, with a 7% growth in revenue, 25% increase in operating profit, and 23% increase in non-GAAP operating profit. The company achieved an operating cash flow of $402 million, demonstrating robust patient and customer demand for its products and software solutions. ResMed's focus on innovation and operational efficiencies led to double-digit growth in mask and accessories revenue, improved margins, and increased profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.89%
Tags
-
Rhea-AI Summary
ResMed (RMD) to Release Q3 Fiscal Year 2024 Financial Results on April 25, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
conferences earnings
-
Rhea-AI Summary
ResMed (RMD) releases results of its 2024 Global Sleep Survey, revealing significant sleep challenges worldwide. 40% of respondents get no more than three nights of good sleep per week. Over 36,000 participants across 17 markets provided insights on sleep patterns and behaviors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
none
Rhea-AI Summary
ResMed launches the AirFit F40, an ultra-compact full-face mask designed to enhance sleep apnea therapy by combining comfort with effectiveness. The mask features a soft silicone AdaptiSeal™ cushion, providing a secure seal and comfort for users. The U.S. launch aims to improve therapy compliance for individuals with sleep apnea.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.74%
Tags
none
-
Rhea-AI Summary
ResMed (RMD) launches AirCurve 11 series devices, enhancing device therapy options for sleep apnea patients. The devices offer advanced features like Care Check-in, Personal Therapy Assistant, and compatibility with AirView and myAir app to support patients and provide insights to clinicians.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.84%
Tags
none
-
Rhea-AI Summary
ResMed Inc. (RMD) announced its second-quarter fiscal year 2024 results, with a 12% year-over-year revenue growth to $1.2 billion and a 2% decrease in operating profit. However, non-GAAP operating profit increased by 20%. The company also resumed its share repurchase program, repurchasing $50 million during the quarter. The CEO highlighted strong double-digit growth across device, masks and accessories, and residential care software businesses, as well as the successful launch of the latest generation platform, AirSense 11, into new markets and geographies globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.48%
Tags
Rhea-AI Summary
ResMed (RMD) to Release Q2 Fiscal Year 2024 Financial and Operational Results on January 24, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
conferences earnings
-
Rhea-AI Summary
ResMed (RMD) CEO Mick Farrell to Present at J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.01%
Tags
none
-
Rhea-AI Summary
ResMed (RMD) conducts a voluntary global field action to update its guides for all masks with magnets to inform users, ensuring safety when used in accordance with the updated Instructions for Use.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none
Rhea-AI Summary
ResMed (NYSE: RMD, ASX: RMD) secured a significant victory as the United States Patent Trial and Appeals Board invalidated the claims asserted by New York University (NYU) against ResMed, based on seven NYU patents. The PTAB judges found all challenged claims across the seven patents to be invalid, upholding ResMed's commitment to providing leading therapy solutions through sustained investment in research and development for over 30 years, resulting in more than 9,500 issued or pending patents and designs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
none
Resmed Inc.

NYSE:RMD

RMD Rankings

RMD Stock Data

27.34B
145.65M
0.82%
57.19%
5.37%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
San Diego

About RMD

at resmed (nyse: rmd, asx: rmd) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. our cloud-connected medical devices transform care for people with sleep apnea, copd and other chronic diseases. our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. by enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries.